Renowned Liver Disease Specialist Named Director of Hepatology at NYU Langone Health
A distinguished clinician and prolific researcher, Dr. Jacobson’s work has been instrumental in the global development of antiviral therapy for viral hepatitis. He has been involved in more than 100 trials of novel, direct-acting antiviral drugs for interferon-based and direct-acting antiviral therapy, including some of the field’s most promising studies, such as ADVANCE (telaprevir), QUEST-1 (simeprevir), POSITRON (sofosbuvir), STARTVerso3 (faldaprevir), and POLARIS-2 (sofosbuvir/velpatasvir/voxilaprevir). He also was the national principal investigator for the WIN-R trial, which established the role of weight-based ribavirin dosing and yielded important insights into the treatment of hepatitis C infection in African Americans.
Dr. Jacobson joins NYU Langone Health from Mount Sinai Beth Israel, where he held the position of chair of the Department of Medicine. Prior to that position, he served as chief of the Division of Gastroenterology and Hepatology and medical director of the Center for the Study of Hepatitis C at Weill Cornell.
“Dr. Jacobson’s work has had a tremendous impact on the care of patients with hepatitis C, transforming this infection from a chronic disease to one that can be cured. His recruitment to NYU Langone greatly enhances our ability to treat patients, strengthens our understanding of liver disease through research, and broadens our education of the next generation of physicians,” says Mark B. Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology. “Having someone of Dr. Jacobson’s caliber join our outstanding hepatology faculty elevates the entire division, allowing us to provide the best possible care to those we serve.”
At NYU Langone Health, Dr. Jacobson will maintain an active practice in hepatology, gastroenterology, and endoscopy while overseeing all of the division’s hepatology service lines. He will work closely with NYU Langone’s Transplant Institute to identify and treat patients in need of liver transplants. Additionally, he will build further upon the foundation of the already active clinical research program in liver diseases at NYU Langone and participate in the education of house staff and fellows.
About Dr. Jacobson
An alumnus of Columbia University College of Physicians and Surgeons, Dr. Jacobson completed his residency in internal medicine at the University of California, San Francisco and a fellowship in gastroenterology at Massachusetts General Hospital. He then joined the faculty at New York Presbyterian/Weill Cornell, where he worked for over three decades.
A prolific researcher, Dr. Jacobson has published over 200 peer-reviewed articles in numerous top-tier publications includingThe New England Journal of Medicine, The Lancet, and Gastroenterology. He has edited two books on endoscopic retrograde cholangiopancreatography (ERCP) and a volume on hepatitis B for Clinics in Liver Disease. Additionally, he has served as an associate editor of the Journal of Hepatology, and on the editorial boards of Hepatology, Alimentary Pharmacology and Therapeutics, and Digestive Diseases and Sciences.
Dr. Jacobson also served on the examination committees of the American Board of Internal Medicine, for both gastroenterology and transplant hepatology, and is a past president of both the New York Society for Gastrointestinal Endoscopy and the New York Gastroenterological Association. He has been co-chair of the annual Viral Hepatitis Congress in Frankfurt, Germany, for the past five years. He is a Fellow of the American College of Physicians, the American Gastroenterological Association, the American College of Gastroenterology, and the American Association for the Study of Liver Diseases, and was recently elected as a Fellow of the Royal College of Physicians in London.
“I am honored to join a division and institution where the mission of excellence in patient care, education, and research are embodied in every member of the team,” says Dr. Jacobson. “I look forward to working with the group of hepatologists, surgeons, and other specialists who have done so much to build the outstanding program in liver diseases at NYU Langone.”